Recently Approved

February 2009
Pharmaceutical Representative;Feb2009, Vol. 39 Issue 2, p12
The article offers information on the clinical drugs approved by the U.S. Food and Drugs Administration (FDA). Gleevec, Novartis AG's treatment of adult patients who underwent surgery for Kit (CD117)-positive gastrointestinal stromal tumors, has been authorized by FDA for new indication. FDA has permitted marketing authorization for GlaxoSmithKline's Promacta for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura.


Related Articles

  • Bioalliance Pharma files NDA for candidiasis drug.  // PharmaWatch: Biotechnology;Aug2009, Vol. 8 Issue 8, p12 

    The article reports on the new drug application of French biopharmaceutical company BioAlliance Pharma to the U.S. Food and Drug and Administration (FDA) in the U.S. BioAlliance has passed an drug application to FDA for the marketing approval of Loramyc, a mocuadhesive buccal tablets for the...

  • Novartis launches schizophrenia drug in US.  // PharmaWatch: CNS;Feb2010, Vol. 9 Issue 2, p11 

    The article reports on the announcement of Novartis AG that its Fanapt tablets, a drug for the treatment of schizophrenia in adults, are now available in the U.S. It mentions that the Food and Drug Administration (FDA) approved the drug in May 2009 basing on the results of two placebo and...

  • The number of new medicines approved or pending approval is on the rise on both sides of the Atlantic, painting an encouraging picture for the global drugs industry as it emerges from a wave of patent expiries.  // MondayMorning;12/24/2012, Vol. 20 Issue 49, p1 

    The article informs about the several new medicines approval by U.S. Food and Drug Administration (FDA) in the U.S. It informs about the approval of drugs for several diseases which includes drugs for leukemia from Ariad Pharmaceuticals Inc., anthrax from the company GlaxoSmithKline and...

  • FDA ROUNDUP.  // MondayMorning;8/20/2012, Vol. 20 Issue 33, p1 

    The article informs that the U.S. Food and Drug Administration (FDA) has approved the manufacturing of flu vaccine by GlaxoSmithKline PLC in London, England. It states that each year the FDA works with other federal agencies and global health experts to design a vaccine to protect against the...

  • Pipeline.  // Medical Marketing & Media;Sep2009, Vol. 44 Issue 9, p12 

    The article offers news briefs related to drug approvals from the U.S. Food and Drug Administration. The Hiberix, a booster shot for children 15 months to four years of age, of GlaxoSmithKline has received approval. An approval for Embeda, a schedule II opioid analgesic for moderate to severe...

  • Decisions Update.  // PharmaWatch: Cancer;Aug2010, Vol. 9 Issue 8, p10 

    The article offers news briefs related to drug approval. GlaxoSmithKline (GSK) has received the European Union (EU) authorization grant for its breast cancer drug. Novartis AG has earned an approval from the U.S. Food and Drug Administration (FDA) for its leukemia drug. Celgene International...

  • Safety Requirements Slow Drug Approvals. Wechsler, Jill // Applied Clinical Trials;Nov2009, Vol. 18 Issue 11, p24 

    The article reports on the slow pace of drug approval by the Food and Drug Administration (FDA) in the U.S. It states that the approval of the FDA Amendments Act of 2007 poses new requirements for assessing postmarket studies and determine the need for Risk Evaluation and Mitigation Strategies...

  • FDA Needs to Enhance Its Oversight of Drugs Approved on the Basis of Surrogate Endpoints. Crosse, Marcia // GAO Reports;10/26/2009, preceding p1 

    The article focuses on a study by the U.S. Government Accountability Office (GAO) on approved drug applications based on surrogate endpoints under Food and Drug Administration's (FDA) accelerated and traditional approval process and the FDA's oversight of postmarketing studies. FDA is...

  • FDA ROUNDUP.  // MondayMorning;7/30/2012, p1 

    The article offers news briefs related to the approval of drugs and clearances given by the U.S. Food and Drug Administration (FDA). Amarin Corp. has received the approval of its first product, a drug indicated to combat blood fat. A marketing clearance was given to Horizon Pharma Inc. for its...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics